Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Public ClinicalTrials.gov record NCT02388906. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Study identification
- NCT ID
- NCT02388906
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 906 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Drug
- Nivolumab Drug
- Placebo matching Ipilimumab Other
- Placebo matching Nivolumab Other
Drug · Other
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2015
- Primary completion
- Nov 25, 2018
- Completion
- Oct 15, 2024
- Last update posted
- Apr 23, 2025
2015 – 2024
United States locations
- U.S. sites
- 35
- U.S. states
- 22
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0036 | Little Rock | Arkansas | 72205 | — |
| Local Institution - 0117 | La Jolla | California | 92093-0698 | — |
| Local Institution - 0189 | Los Angeles | California | 90025 | — |
| Local Institution - 0021 | San Francisco | California | 94109 | — |
| Local Institution - 0006 | San Francisco | California | 94143 | — |
| Local Institution - 0010 | Aurora | Colorado | 80045 | — |
| Local Institution - 0004 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0012 | Jacksonville | Florida | 32207 | — |
| Local Institution - 0019 | Miami Beach | Florida | 33140 | — |
| Local Institution - 0030 | Orlando | Florida | 32806 | — |
| Local Institution - 0032 | Tampa | Florida | 33612 | — |
| Local Institution - 0016 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0106 | Chicago | Illinois | 60637 | — |
| Local Institution - 0013 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0170 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0171 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0015 | Ann Arbor | Michigan | 48109-5869 | — |
| Local Institution - 0002 | Robbinsdale | Minnesota | 55407 | — |
| Local Institution - 0017 | St Louis | Missouri | 63110 | — |
| Local Institution - 0123 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0095 | New Brunswick | New Jersey | 08903 | — |
| Local Institution - 0024 | New York | New York | 10016 | — |
| Local Institution - 0033 | New York | New York | 10065 | — |
| Local Institution - 0003 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0025 | Durham | North Carolina | 27710 | — |
| Local Institution - 0157 | Columbus | Ohio | 43210 | — |
| Local Institution - 0031 | Portland | Oregon | 97213 | — |
| Local Institution - 0029 | Portland | Oregon | 97239 | — |
| Local Institution - 0022 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0001 | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 0026 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0014 | Nashville | Tennessee | 37203-1624 | — |
| Local Institution - 0005 | Dallas | Texas | 75246 | — |
| Local Institution - 0027 | Charlottesville | Virginia | 22908 | — |
| Local Institution - 0126 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02388906, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02388906 live on ClinicalTrials.gov.